Category: Uncategorized
-
Regenicin, Inc. Completes Successful Pre-IND Meeting with Food and Drug Administration (FDA) for its New Autologous Cultured Skin Substitute, NovaDerm®
•
(Little Falls, NJ) – November 1, 2016 – Regenicin, Inc., a biotechnology company a biotechnology company specializing in the development and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, today announced that they have completed the Pre-IND (Investigational New Drug) Meeting via teleconference with…